Literature DB >> 15602720

Recombinant nucleoprotein-based serological diagnosis of Crimean-Congo hemorrhagic fever virus infections.

Masayuki Saijo1, Qing Tang, Bawudong Shimayi, Lei Han, Yuzhen Zhang, Muer Asiguma, Dong Tianshu, Akihiko Maeda, Ichiro Kurane, Shigeru Morikawa.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) using recombinant nucleoprotein (rNP) was reported for the detection of immunoglobulin G (IgG) antibodies to Crimean-Congo hemorrhagic fever (CCHF) virus (CCHFV). The immunoglobulin M (IgM)-capture ELISA was developed for the diagnosis of CCHFV infections, using CCHFV rNP as an antigen. These newly developed assays were applied to a study of a CCHF-outbreak and evaluated with sera collected from patients diagnosed as having CCHF by positive reverse transcription-polymerase chain reaction (RT-PCR) and by detection of IgG response. IgM antibodies to CCHFV were detected in 10 of the 13 patients. IgM antibodies to the rNP of CCHFV were detected by the CCHFV rNP-based IgM-capture ELISA in all 6 patients in whom IgG responses were demonstrated, while it was not detected in the 10 patients in whom IgG responses were not demonstrated. Furthermore, the IgM antibodies were detected in 6 of the 61 residents living a CCHF endemic area during the endemic season, while it was not detected in any of the 48 Japanese residents that had never visited the CCHF endemic area. It is concluded that this newly developed CCHFV rNP-based IgM-capture ELISA is a useful method for the diagnosis of CCHFV infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15602720     DOI: 10.1002/jmv.20270

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  12 in total

Review 1.  Diagnostic Testing for Crimean-Congo Hemorrhagic Fever.

Authors:  Vanessa N Raabe
Journal:  J Clin Microbiol       Date:  2020-03-25       Impact factor: 5.948

2.  Development of recombinant nucleoprotein-based diagnostic systems for Lassa fever.

Authors:  Masayuki Saijo; Marie-Claude Georges-Courbot; Philippe Marianneau; Victor Romanowski; Shuetsu Fukushi; Tetsuya Mizutani; Alain-Jean Georges; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

Review 3.  Crimean-Congo hemorrhagic fever and expansion from endemic regions.

Authors:  Jessica R Spengler; Éric Bergeron; Christina F Spiropoulou
Journal:  Curr Opin Virol       Date:  2019-01-16       Impact factor: 7.090

4.  An update on crimean congo hemorrhagic Fever.

Authors:  Suma B Appannanavar; Baijayantimala Mishra
Journal:  J Glob Infect Dis       Date:  2011-07

5.  Detection of IgG antibody against Crimean-Congo haemorrhagic fever virus using ELISA with recombinant nucleoprotein antigens from genetically diverse strains.

Authors:  A Rangunwala; R R Samudzi; F J Burt
Journal:  Epidemiol Infect       Date:  2013-12-13       Impact factor: 4.434

6.  Fine epitope mapping of the central immunodominant region of nucleoprotein from Crimean-Congo hemorrhagic fever virus (CCHFV).

Authors:  Dongliang Liu; Yang Li; Jing Zhao; Fei Deng; Xiaomei Duan; Chun Kou; Ting Wu; Yijie Li; Yongxing Wang; Ji Ma; Jianhua Yang; Zhihong Hu; Fuchun Zhang; Yujiang Zhang; Surong Sun
Journal:  PLoS One       Date:  2014-11-03       Impact factor: 3.240

7.  Long-lived CD8+ T cell responses following Crimean-Congo haemorrhagic fever virus infection.

Authors:  Dominique Goedhals; Janusz T Paweska; Felicity J Burt
Journal:  PLoS Negl Trop Dis       Date:  2017-12-19

Review 8.  Development of vaccines against Crimean-Congo haemorrhagic fever virus.

Authors:  Stuart D Dowall; Miles W Carroll; Roger Hewson
Journal:  Vaccine       Date:  2017-07-04       Impact factor: 3.641

Review 9.  Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers.

Authors:  Shuetsu Fukushi; Hideki Tani; Tomoki Yoshikawa; Masayuki Saijo; Shigeru Morikawa
Journal:  Viruses       Date:  2012-10-12       Impact factor: 5.048

Review 10.  Crimean-Congo haemorrhagic fever.

Authors:  Onder Ergönül
Journal:  Lancet Infect Dis       Date:  2006-04       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.